Hematologic Malignancy
Childhood Non-Hodgkin Lymphoma
CI-CAN-00002301Explore in graph →
PediatricHematologic9 active trials
- NCIt
- C7706
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00002301Explore in graph →
Clinical trials
79 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (8)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05857969 | Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling | recruiting | Phase 1 | 65 | Florida International UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05418088 | Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies | recruiting | Phase 1 | 54 | Sumithira VasuOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT03817320 |
| PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma |
| active not recruiting |
| Phase 1 / Phase 2 |
| 24 |
| Therapeutic Advances in Childhood Leukemia ConsortiumOTHER |
| 2 |
| Jun 17, 2025 |
| clinicaltrials |
Data updated 23 days agoSource updated Aug 26, 2026source: clinicaltrials